Ascendis Pharma A/S Announces Participation in ENDO Online 2020

COPENHAGEN, Denmark, June 08, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced presentations related to its rare disease endocrinology programs at ENDO Online 2020, the annual meeting of the Endocine Society, taking place June 8 - 22, 2020.

“The fliGHt Trial data presented at ENDO Online demonstrate that subjects taking daily somatropin can safely switch to TransCon hGH, our investigational long-acting prodrug that releases somatropin, with consistent and predictable efficacy,” said Jan Mikkelsen, Ascendis Pharma’s President and CEO. “Further, the interim data from heiGHt Trial subjects who continued in the enliGHten long-term extension trial demonstrated the maintenance of a height advantage in subjects initially treated with TransCon hGH beyond the first year of therapy. We remain on track to submit our marketing applications in the United States this quarter and in Europe in the third quarter.”

He continued, “Additionally, our recently-reported top-line PaTH Forward data for TransCon PTH, our long-acting prodrug of parathyroid hormone, demonstrated the ability of TransCon PTH to replace standard of care over a short, four-week fixed dose blinded period, highlighting its potential as a PTH hormone replacement therapy to treat hypoparathyroidism.”

ENDO Online 2020 Presentation Details

Oral Presentation
Title	Date Time
Phase 3 fliGHt Trial: Experience of Switching from Daily Growth Hormone Therapy to Once-weekly TransCon hGH in Children with Growth Hormone Deficiency	Monday, June 8 8:00 a.m. (Pacific time) 11:00 a.m. (Eastern time)
Abstracts
Title	Reference
Maintenance of Favorable Treatment Effect of Once-Weekly TransCon hGH for Children with Growth Hormone Deficiency: Interim Analysis from the enliGHten Long-Term Extension Trial	Journal of the Endocrine Society, Volume 4, Issue Supplement_1, April-May 2020
Design of the PaTH Forward Phase 2 Trial of TransCon PTH, a Long-acting PTH, in Patients with Hypoparathyroidism	Journal of the Endocrine Society, Volume 4, Issue Supplement_1, April-May 2020

If you are a healthcare provider who would like more information, please contact: [e-mail].